Immunomodulatory Agents and Factors in Poor Hematopoietic Stem Cell Mobilization: Current Strategies and Future Prospects
Stem Cell Reviews and Reports · 2026-04 · 22 (3) · 1127-1138
DOI: 10.1007/s12015-025-11047-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Reviews and Reports, online erschienen am 04.01.2026. Verfasst von Iraj Alipourfard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, Warsaw, 02-097, Poland. iraj.ali…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Mobilization, Hematopoietic Stem Cells, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Hematopoietic stem cell (HSC) mobilization is a critical step in bone marrow transplantation for treating hematological malignancies and other disorders. Since poor mobilization affects 10–20% of patients, it can cause failure of the transplant and complications in clinical outcomes. There are several important factors that modify poor mobilization, of which immunomodulatory agents and factors are most potentially causative. This study examines the role of immunomodulatory factors in the process of HSC mobilization from the bone marrow. It presents a prospect based on the latest preclinical studies and clinical trials. We explore standard agents, such as granulocyte colony-stimulating factor (G-CSF) and plerixafor, alongside emerging immunomodulatory cytokines, including interleukin-8 (IL-8) and interleukin-1 (IL-1), and their impact on the bone marrow (BM) niche. Strategies to enhance mobilization in poor responders, including combination therapies and niche-targeting approaches, are critically assessed. Looking forward, we propose innovative prospects, such as epigenetic reprogramming, nanotechnology-based delivery, and artificial intelligence (AI)-driven personalization, to address current gaps and improve mobilization efficacy. This article aims to guide future research and clinical practice in optimizing HSC transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, Warsaw, 02-097, Poland. iraj.alipourfard@wum.edu.pl.
- Department of Pathology, University of Pittsburgh, PA, Pittsburgh, USA.
- Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, Warsaw, 02-097, Poland.
- Division of Neuroscience, Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Zitieren
APA
Alipourfard, I., Mokhtari, T., Lesniak, A., Saharkhiz, S., & Zelazewska, Z. (2026). Immunomodulatory Agents and Factors in Poor Hematopoietic Stem Cell Mobilization: Current Strategies and Future Prospects. Stem Cell Reviews and Reports, 22(3), 1127-1138. https://doi.org/10.1007/s12015-025-11047-8
Vancouver
Alipourfard I, Mokhtari T, Lesniak A, Saharkhiz S, Zelazewska Z. Immunomodulatory Agents and Factors in Poor Hematopoietic Stem Cell Mobilization: Current Strategies and Future Prospects. Stem Cell Reviews and Reports. 2026;22(3):1127-1138. doi:10.1007/s12015-025-11047-8
BibTeX
@article{Alipourfard2026,
author = {Alipourfard, Iraj and Mokhtari, Tahere and Lesniak, Anna and Saharkhiz, Saber and Zelazewska, Zuzanna},
title = {Immunomodulatory Agents and Factors in Poor Hematopoietic Stem Cell Mobilization: Current Strategies and Future Prospects},
journal = {Stem Cell Reviews and Reports},
year = {2026},
volume = {22},
number = {3},
pages = {1127--1138},
doi = {10.1007/s12015-025-11047-8}
}
EUVIMED